← Human Trials & Peer-Reviewed Studies
Effects of methylene blue on postoperative low-back pain and functional outcomes after lumbar open discectomy: a triple-blind, randomized placebo-controlled trial
Plain-language guide to PMID 26360148 (2016): placebo-controlled randomized controlled trial study of Methylene blue (non-peptide stack partner) in 130 patients.
Key Facts
- PMID
- 26360148
- Journal
- Journal of neurosurgery. Spine
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Farrokhi MR et al. (4 authors)
- DOI
- 10.3171/2015.3.SPINE141172
What This Study Did, in Plain Language
What Was Tested
Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.
Despite advances in surgical and anesthesiology techniques, many patients continue to experience postoperative pain after lumbar disc operations.
Who Took Part
The study group was 130 patients.
The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.
The comparison arm used a placebo, so changes seen with Methylene blue (non-peptide stack partner) could be set against what happens without it.
This is a prospective, randomized, triple-blind, placebo-controlled clinical trial, which was conducted at Shiraz University of Medical Sciences between July 2011 to January 2012.
What Was Measured
Topics PubMed links to this paper include Disability Evaluation, Diskectomy, Intervertebral Disc Displacement, Low Back Pain, Lumbar Vertebrae, Methylene Blue and Quality of Life.
Author keywords: 5-HT = 5-hydroxytryptamine (serotonin), BMI = body mass index, LBP = low-back pain, MAO = monoamine oxidase, MB = methylene blue and ODI = Oswestry Disability Index.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Methylene blue (non-peptide stack partner) in 130 patients.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2016 (Journal of neurosurgery. Spine), a journal based in United States.
More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.
Our Notes on the Compound
Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.